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Abstract
Membrane proteins (MPs) are responsible for the interface between the exterior
and the interior of the cell. These proteins are implicated in numerous diseases,
such as cancer, cystic ﬁbrosis, epilepsy, hyperinsulinism, heart failure, hypertension
and Alzheimer’s disease. However, studies on these disorders are hampered by
a lack of structural information about the proteins involved. Structural analysis
requires large quantities of pure and active proteins. The majority of medically and
pharmaceutically relevant MPs are present in tissues at very low concentration, which
makes heterologous expression in large-scale production-adapted cells a prerequisite
for structural studies. Obtaining mammalian MP structural data depends on the
development of methods that allow the production of large quantities of MPs.
This review focuses on the different heterologous expression systems, and the
puriﬁcation strategies, used to produce large amounts of pure mammalian MPs for
structural proteomics. Copyright  2002 John Wiley & Sons, Ltd.
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Introduction
Proteomics is more than the systematic partition-
ing and referencing of all the proteins produced
in an organism, it is also the study of how pro-
teins change structure, interact with other pro-
teins, and ultimately give rise to disease or health
in an organism [1]. Integral membrane proteins
(MPs) account for 20–25% of all open reading
frames in fully sequenced genomes. These pro-
teins are of central importance to living cells.
They are required for transport processes, sens-
ing changes in the cellular environment, trans-
mission of signals, and control of cell–cell con-
tacts. MPs are implicated in cancer, cystic ﬁbrosis,
epilepsy, hyperinsulinism, heart failure, hyperten-
sion and Alzheimer’s disease, but studies on these
and other disorders are hampered by a lack of
information about the proteins involved. Know-
ing the structure of MPs is an essential prerequi-
site to understanding how MPs function and, fur-
ther, how their functions can be modiﬁed by small
molecules. This is of paramount importance in
the pharmaceutical industry, which produces many
drugs that bind to MPs (e.g. Prozac and Imigram),
and recognizes the potential of many recently iden-
tiﬁed G protein-coupled receptors, ion channels and
transporters as targets for future drugs. However,
whereas high-resolution structures are available for
a myriad of soluble proteins, three-dimensional
(3D) structures have so far been obtained for only
34 intregral MPs, the majority of which are from
prokaryotic organisms, with only ﬁve being mam-
malian MPs [2,3,4,5,6] (see http://www.mpibp-
frankfurt.mpg.de/michel/public/memprotstruct.
html). One of the major factors in dictating why
these particular MPs were crystallized was their
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natural abundance, circumventing all the difﬁcul-
ties associated with overexpression. However, the
majority of medically and pharmaceutically rele-
vant MPs are present in tissues at very low con-
centration, making overexpression in heterologous
cells suitable for large-scale production a prereq-
uisite for structural studies. The relative ease of
overexpression of many bacterial transporters is
making them prime candidates for structure deter-
mination [7,8,9]. Mammalian MPs are far more
difﬁcult to purify in large amounts than prokaryotic
MPs, due to the need to express them in heterol-
ogous systems to achieve large-scale production.
This review focuses on the different heterologous
expression systems and puriﬁcation strategies used
to produce amounts of pure mammalian MPs that
are adequate for structural analysis.
Heterologous expression systems
Chinese hamster ovary (CHO) cells
For large-scale commercial production of thera-
peutically important proteins like erythropoietin,
recombinant CHO (rCHO) cells have been adapted
to grow in suspension in serum free media which
is an advantage in terms of cost, as well as of
biosafety [10]. This suspension culture of rCHO
cells has been shown to be an efﬁcient system
for expressing the rat 5-HT2 serotonin receptor for
drug discovery [11], but no MP has been puriﬁed
from this host in an amount sufﬁcient for struc-
tural analysis.
Insect cells
Baculovirus-mediated expression in insect cells
such as Spodoptera frugiperda (SF9) is a well-
established approach for the production of recom-
binant glycoproteins. Like rCHO cells, insect
cells can be grown in suspension in serum free
media. The rat synaptic vesicle monoamine trans-
porter [12] and the human α1 glycine receptor [13]
have been functionally overexpressed and puri-
ﬁed from baculovirus-mediated expression sys-
tems, yielding 0.5 mg and 1 mg pure protein/l cell
culture, respectively (Table 1). Recently, heterolo-
gous genes have been shown to be expressed by
stable transfection of insect cells [14]. The major
advantage of this host for expression of mam-
malian MPs is that many processing events known
in mammalian systems also occur in insects [15].
However, large-scale production of MPs using this
system is time-consuming and expensive.
Bacteria
Prokaryotic homologues have been most amenable
for obtaining structural information on MPs
because they can often be expressed in bacteria
in large quantities [16]. However, this method can-
not easily be extended to mammalian MPs, since
these proteins are mostly expressed in inclusion
bodies, from which they are usually impossible
to purify under non-denaturing conditions. How-
ever, derivatives of E. coli BL21(DE3) strain,
CD41(DE3) and CD43(DE3), selected to grow
to high saturation cell density and to overpro-
duce proteins without toxic effect for the host
cell [17], have been successfully used for produc-
tion of mitochondrial MPs [18,19]. Very recently,
the human Na+/glucose transporter has been func-
tionally expressed and puriﬁed using an E. coli
BL21(DE3) mutant (defective in the outer mem-
brane protease OmpT) and incubation tempera-
tures below 20 ◦C, reducing proteolytic degradation
(Table 1) [20]. The green ﬂuorescent protein (GFP)
reporter was used to show that this Na+/glucose
recombinant transporter was inserted into the bac-
terial plasma membrane and not into inclusion bod-
ies [21,20]. In contrast to the case for the sero-
tonin transporter, which could not be functionally
expressed in E. coli [22], cholesterol (a steroid
present in eukaryotic membranes but not in E. coli)
and N-glycosylation (bacteria do not possess glyco-
sylation machinery) are not required for the glucose
transporter to show activity.
Yeast
This simple eukaryotic cell is a multi-purpose
host, performing many of the post-translational
modiﬁcations seen in higher eukaryote cells (gly-
cosylation, disulphide bond formation and pro-
teolytic processing), combined with the ease of
growing a large volume of cells in short period
of time. Cloning, functional expression, identi-
ﬁcation of interacting partners, mutagenesis of
the protein, or its partners, and overexpression
for biophysical analysis can all be achieved in
yeast [23]. Exciting possibilities also exist for the
exploitation of yeast genetics to tailor yeast strains
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Table 1. Examples of mammalian MPs successfully expressed and puriﬁed in heterologous expression systems
MPs expressed
Heterologous
expression
systems Puriﬁcation procedure
Amount of
puriﬁed MP
per culture
(mg/l)
Rabbit SERCA1a Ca2+-ATPase [26] Yeast S. cerevisiae Ni2+ afﬁnity chromatography followed
by reactive red chromatography
0.05
Rat vesicular monoamine transporter [24] Yeast S. cerevisiae Ni2+ afﬁnity chromatography nd
Human P-glycoprotein [25] Yeast S. cerevisiae Ni2+ afﬁnity chromatography 0.4
N-glycosylation mutant mouse and human
P-glycoproteins [31]
Yeast P. pastoris Ni2+ afﬁnity chromatography 1.0
Mutant mouse P-glycoprotein [30] Yeast P. pastoris Ni2+ afﬁnity chromatography 1.0
Biotinylated mouse P-glycoprotein [29] Yeast P. pastoris Ni2+ and avidin afﬁnity chromatography 1.4
Human peptide transporter [32] Yeast P. pastoris Ni2+ afﬁnity chromatography 0.2
Human Na+/glucose transporter [21] Bacteria E. coli, BL21(DE3) Anti-FlagM2 afﬁnity chromatography 0.3
Human α1 glycine receptor [13] Insect cells Aminostrychnine afﬁnity
chromatography
1.0
Rat synaptic-vesicle monoamine
transporter [12]
Insect cells Ni2+ afﬁnity chromatography 0.5
nd, not determined.
so that they are optimized for the expression
of MPs. Two yeast species have so far been
used successfully for heterologous expression of
mammalian MPs: Saccharomyces cerevisiae and
Pichia pastoris.
Saccharomyces cerevisiae has been success-
fully used to functionally express and purify
several mammalian MPs, like the human P-
Glycoprotein [24], the rat vesicular monoamine
transporter [25] and, very recently, the rabbit
SERCA1a Ca2+-ATPase [26] (Table 1). The exp-
ression vectors used are 2µ multicopy plasmids
with the inducible GAL1 promoter or the strong
constitutive promoter from the yeast plasma mem-
brane ATPase (PMA1). Fliger et al. [24] show that
human P-glycoprotein expression can reach 8%
of total MPs using a protease-deﬁcient strain, and
glycerol (thought to enhance the post-translational
stability of the protein). The level of expression
reached is comparable to that of mammalian cells
(COS, HEK293), yet at only a fraction of the cost,
time and effort. Yelin and Schuldiner [25] showed
that the expression of the vesicular monoamine
transporter was enhanced by modiﬁcation of certain
codons in the translation initiation region to codons
preferred by S. cerevisiae, and by reducing the tem-
perature to 16 ◦C, which also allowed the expressed
transporters to undergo core glycosylation. Lower-
ing the temperature from 30 ◦C to 16–18◦C seems
to be a general rule for enhancing the functional
expression of MPs, since it has also been observed
for the SERCA1a Ca2+-ATPase [26].
The methylotrophic yeast, P. pastoris, has been
used for the expression of more than 300 heterol-
ogous proteins and has been used successfully as
a tool for large-scale recombinant soluble protein
production [27]. P. pastoris is a poor fermenter, a
major advantage relative to S. cerevisiae.I nh i g h
cell density cultures, ethanol (a product of S. cere-
visiae fermentation) rapidly builds to toxic levels
that limit further growth and foreign protein pro-
duction. With its preference for respiratory growth,
P. pastoris can be cultured at extremely high densi-
ties (500OD600 U/ml) in the controlled environment
of a fermenter. Moreover, foreign genes are sta-
bly integrated in single or multiple copy behind
the AOX1 (alcohol oxidase 1) promoter, one of the
strongest, most regulated promoters known. How-
ever, the full potential for P. pastoris as a host
for MPs is yet to be realized, although promis-
ing results have been obtained with the puriﬁca-
tion of about 0.2 mg/l culture of the human β2
adrenergic receptor [28], the human and mouse
P-glycoproteins [29,30,31] and the human peptide
transporter [32] (Table 1).
Although yeast appears to be the most amenable
expression system for many mammalian MPs,
some MPs cannot be functionally expressed in
yeast, e.g. the serotonin transporter (SERT) can
only be functionally expressed in insect and
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mammalian cells due to the requirement for:
N-linked glycosylation (for folding and stability of
the transporter), the molecular chaperone calnexin
(involved in the folding of SERT) and cholesterol
(to maintain the protein structure) [22].
Puriﬁcation strategies
Most of the mammalian MPs successfully expres-
sed in heterologous systems have been puriﬁed
using a single-step afﬁnity chromatography Ni2+-
NTA column that binds a polyHis tag fused at
the N- or C-terminus of the protein (Table 1).
This single puriﬁcation step results in a 70–80%
enrichment of the protein of interest. Further chro-
matographic steps are required to obtain pure pro-
tein, often resulting in a dramatic reduction in the
amount of protein.
S´ eraphin and collaborators have developed a
puriﬁcation strategy allowing efﬁcient recovery of
proteins present at low levels in the cell: the tan-
dem afﬁnity puriﬁcation (TAP) method [33]. IgG-
binding units of protein A from Staphylococcus
aureus (ProtA) and the calmodulin binding pep-
tide (CBP) were fused in tandem, linked by a TEV
cleavage site. The TAP tag is fused to the protein
of interest and the construct is introduced into the
cognate host cell or organism. The TAP method
has been optimized for rapid puriﬁcation of pro-
teins expressed at their natural level, under native
conditions, allowing protein complex identiﬁcation
and proteome exploration [34]. This method could
be useful for large-scale puriﬁcation of mammalian
MPs. The fusion of a TAP tag at the N- or C-
terminus of the MP of interest would allow the
use of two afﬁnity chromatography steps for efﬁ-
cient recovery of that MP. Because it is generic and
rapid, the TAP procedure may constitute an impor-
tant new tool for structural proteomics of MPs.
Structural analysis
Structural information is a powerful tool for
understanding the working mechanisms of macro-
molecules at the molecular level. Structural pro-
teomics is therefore of great interest to the phar-
maceutical industry: the 3D structure of biomedical
target proteins can be exploited to develop small
molecule effectors against diseases. At the funda-
mental level, structural proteomics is a cornerstone
of functional genomics: the uncovering of the bio-
chemical and cellular function of all ORFs in an
organism. The 3D structure of a protein can be
used to deduce function from unknown proteins, to
make molecular models of related proteins, which
can then serve biochemical studies and to pre-
dict interactions with small molecule effectors or
protein partners (van Tilbeurgh, ‘From Genome to
Life’ Carg` ese Summer School 2002). The genomic
approach that consists of resolving the structure of
several bacterial members of an MP family has
been developed for different types of MPs, such as
the ABC transporters MsbA and BtuCD [9,35] and
chloride channels [8]. Other groups have chosen
to perform crystallographic studies on MPs from
thermophilic archaea because they are more sta-
ble and easier to purify [36,37]. This approach is
an alternative to mammalian MP structure determi-
nation because bacterial MPs are usually easier to
express, purify and crystallize, and the 3D struc-
tures can serve as models for the study of their
mammalian homologues.
The different structural proteomics projects under
development for Methanobacterium thermoautotro-
phicum [36] and yeast (http://genomics.eu.org/)
provide databases with a number of soluble protein
structures, but very few MP structures.
For X-ray crystallography, the techniques used
are nearly identical to that used for soluble proteins,
except that the object being crystallized is not just
protein but a protein–detergent complex. Obtaining
crystals that diffract well requires a homogeneous
protein–detergent complex that may be affected by
the presence of impurities, especially lipids, which
are difﬁcult to remove because of their stabilizing
effect. Despite these difﬁculties, the number of 3D
structures of integral MPs is increasing rapidly: 21
of the 34 known integral MP structures have been
solved in the last 3 years (see http://www.mpibp-
frankfurt.mpg.de/michel/public/memprotstruct.
html).
Two methods have improved the success rate
in 3D crystallization: the use of antibody Fv
fragments to increase the effective hydrophilic area
of the MP [38,39,40]; and 3D crystallization in
cubic lipid phases, which provides an environment
that allows solubilized MPs to diffuse and merge
into micro-crystals within the labyrinth of the cubic
lipid system [41,42,43,44].
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A powerful alternative is reconstitution into
two-dimensional (2D) crystals in the presence of
lipids [45], restoring the native environment of
MPs as well as their biological activity. These
crystals can be studied both by cryo-electron
microscopy, which allows the 3D structure of the
vitriﬁed protein to be assessed at atomic resolu-
tion, and atomic force microscopy (AFM), which
depicts biological membranes in aqueous solutions
and permits the monitoring of the movement of sin-
gle polypeptide loops. The combined application of
these two techniques can establish the 3D structure
of MPs and allow the visualization of their confor-
mational changes during catalytic cycles [46].
Spectroscopic techniques such as ﬂuorescence
and infrared are useful to probe aspects of trans-
membrane segment orientation, structure and dyna-
mics in lipid bilayers. The ﬂuorescence from tryp-
tophan contains valuable information about the
local environment of the indole side-chain. This
environment sensitivity, coupled with the abil-
ity to incorporate a single tryptophan residue
at speciﬁc sites in a polypeptide sequence, has
provided the membrane biophysicist with tools
for examining the structure and dynamics of
MPs [47,48].
Conclusion
MPs represent one of the most challenging classes
of proteins in the areas of overexpression/puriﬁcat-
ion and structural biochemistry. The heterologous
expression problems associated in particular with
mammalian MPs are a major bottleneck to over-
come in studies of the structure and function of
these MPs. Puriﬁcation of mammalian MPs such
as the serotonin transporter (SERT) requires the
growth of tens of litres of insect or mammalian
cells, which is extremely time consuming and
costly. The use of yeast, and to a lesser extent
of bacteria, as hosts for mammalian MP overex-
pression has been heavily studied over the last few
years and is becoming more and more success-
ful. Some prerequisites seem to favour mammalian
MP expression in these hosts: the modiﬁcation
of the codon usage of the initiation region with
codons shown to stabilize the mRNA in yeast, the
combined use of protease-deﬁcient strains and a
growth temperature of 16–18 ◦C to avoid prote-
olytic degradation and favour core glycosylation,
and the use of chemical chaperones such as glyc-
erol to stabilize proteins. Moreover, the tandem
afﬁnity puriﬁcation strategy should allow more efﬁ-
cient puriﬁcation and facilitate the production of
pure MPs for structural studies. The recent progress
in heterologous expression in bacteria and yeast,
and in puriﬁcation strategies, encourages the devel-
opment of structural proteomics programs on MPs.
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